<DOC>
	<DOCNO>NCT00328159</DOCNO>
	<brief_summary>Usual dietary therapy mitochondrial fatty acid oxidation disorder ( FAO ) base 3 strategy : - limitation lipid intake diet ; - supplementation diet medium-chain triglyceride ( MCT ) patient affected disorder long-chain FAO ; - specific supplementation ( example , L-carnitine ) . These strategy often ineffective . The aim present study evaluate new therapeutic way base underlying energetic defect observe disorder . The long-term goal develop efficient therapy disorder .</brief_summary>
	<brief_title>Nutritional Therapy Deficits Oxidation Mitochondrial Fatty Acids</brief_title>
	<detailed_description>The main specific aim study determine efficiency odd-chain MCT : TRIHEPTANOIN ( Tri-C7 ) metabolites , BETA-HYDROXYPENTANOATE ( BHP ) BETA-KETOPENTANOATE ( BKP ) , potential treatment orale enteral route . These compound efficiently use energy production , despite long-chain FAO enzyme defect . They use alternative metabolic pathway anaplerotic effect due propionyl-CoA production thiolytic cleavage odd carbon ketone body . The efficiency compound compare conventional diet ( MCT ) patient . Because frequent phenotypic variation observe disease , patient control . The protocol study follow 2 center : Dallas , USA ( main investigator : Dr CR Roe ) Paris , France ( main investigator : Dr G TOUATI ) . It plan include 80 patient ( 60 Dallas , 20 Paris ) , next 2 year . The patient affect 6 proven defect specific defect long-chain FAO : carnitine palmitoyltransferase 1 ( CPT1 ) , carnitine-acylcarnitine translocase ( CAT ) , carnitine palmitoyltransferase 2 ( CPT2 ) , very-long chain acyl-CoA dehydrogenase ( VLCAD ) , L-3-hydroxy-acyl-CoA dehydrogenase ( LCHAD ) trifunctional protein ( MTP ) . The used methodology control randomize study compare efficiency 2 diet therapy : TRIHEPTANOIN versus conventional MCT . The studied parameter depend disease depend affect organ patient . Main study clinical parameter : survival rate , number metabolic acute decompensation , frequency severity hypoglycemia , frequency severity rhabdomyolyses , evolution cardiac hepatic manifestation , muscular strength , quality life . Main study biological parameter : TRIHEPTANOIN use meal test , modification plasma acylcarnitines profile , modification urinary organic acid , blood measurement CPK transaminase . Cardiac echography perform follow-up cardiomyopathy , ergometric test strength test perform disorder affect muscular function .</detailed_description>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<criteria>Patient enzyme deficiency carnitine palmitoyltransferase 1 ( CPT1 ) , carnitineacylcarnitine translocase ( CAT ) , carnitine palmitoyltransferase 2 ( CPT2 ) , verylong chain acylCoA dehydrogenase ( VLCAD ) , L3hydroxyacylCoA dehydrogenase ( LCHAD ) trifunctional protein ( MTP ) . Covered health social insurance Written inform consent Patient affect FAO dysfunction secondary cause ( e.g . mitochondrial respiratory chain disorder ) Patient suspect FAO disorder proven ( enzymatic molecular test )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>FAO disorder</keyword>
	<keyword>long-chain FAO enzyme defect</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>carnitine palmitoyltransferase 1 ( CPT1 ) ,</keyword>
	<keyword>carnitine-acylcarnitine translocase ( CAT ) ,</keyword>
	<keyword>carnitine palmitoyltransferase 2 ( CPT2 ) ,</keyword>
	<keyword>very-long chain acyl-CoA dehydrogenase ( VLCAD ) ,</keyword>
	<keyword>L-3-hydroxy-acyl-CoA dehydrogenase ( LCHAD )</keyword>
	<keyword>trifunctional protein ( MTP ) .</keyword>
</DOC>